--- title: "TSS Q1 earnings call highlights" type: "News" locale: "en" url: "https://longbridge.com/en/news/285797856.md" description: "TSS (NASDAQ:TSSI) reported a significant year-over-year decline in first-quarter revenue, dropping to $55.3 million from $99 million due to normalized procurement activity. However, executives highlighted growth in the higher-margin systems integration business, which supported profitability and reinforced the company's outlook for 2026." datetime: "2026-05-09T05:45:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285797856.md) - [en](https://longbridge.com/en/news/285797856.md) - [zh-HK](https://longbridge.com/zh-HK/news/285797856.md) --- # TSS Q1 earnings call highlights 5 Small Cap Stocks With Explosive Upside Potential TSS (NASDAQ:TSSI) reported a sharp year-over-year decline in first-quarter revenue as procurement activity normalized from unusually high levels a year earlier, but executives said growth in the company's higher-margin systems integration business helped support profitability and reinforced its 2026 outlook. The company reported first-quarter 2026 revenue of $55.3 million, down from $99 million... ### Related Stocks - [TSSI.US](https://longbridge.com/en/quote/TSSI.US.md) ## Related News & Research - [TSS forecasts 2026 adjusted EBITDA of $20 million-$22 million](https://longbridge.com/en/news/295854103.md) - [TSSI: Rapid revenue and EBITDA growth fueled by AI-driven demand and strategic expansion](https://longbridge.com/en/news/295853506.md) - [Needham & Company LLC Lowers TSS (NASDAQ:TSSI) Price Target to $13.00](https://longbridge.com/en/news/295934180.md) - [TSS Q2 revenue falls 20% and misses analyst estimates](https://longbridge.com/en/news/295840050.md) - [Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook](https://longbridge.com/en/news/296058426.md)